3-{4-[1-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-heptyl]-benzoylamino}-propionic acid | 954148-01-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-{4-[1-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-heptyl]-benzoylamino}-propionic acid
• 英文别名: 3-[[4-[1-[4-[4-(Trifluoromethyl)phenyl]phenyl]octan-2-yl]benzoyl]amino]propanoic acid
• CAS: 954148-01-7
• 化学式: C₃₁H₃₄F₃NO₃
• 分子量: 525.611
• InChiKey: OUQCDAZXVINHKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  38
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
  申请人：Li Jianke

  公开号：US20080280982A1

  公开（公告）日：2008-11-13

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明公开了I式新化合物，或其药学上可接受的盐，其具有葡萄糖原受体拮抗剂或反向激动剂活性，以及制备这些化合物的方法。在另一实施例中，本发明公开了包含I式化合物的药物组合物，以及使用它们治疗糖尿病和其他葡萄糖原相关代谢紊乱等疾病的方法。
• GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
  申请人：Eli Lilly & Company

  公开号：EP1951658A1

  公开（公告）日：2008-08-06
• Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
  申请人：REMD Biotherapeutics, Inc.

  公开号：US20170143673A1

  公开（公告）日：2017-05-25

  The present invention relates to methods for treating or preventing heart failure using a glucagon receptor antagonist or modulator. In various embodiments, the present invention relates to methods for treating post-myocardial infarction heart failure and lateral ventricular (LV) remodeling. In various embodiments, the present invention relates to methods for treating diabetic cardiomyopathy.
• US7863329B2
  申请人：——

  公开号：US7863329B2

  公开（公告）日：2011-01-04
• [EN] GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DU GLUCAGON, LEUR PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2007123581A1

  公开（公告）日：2007-11-01

  [EN] The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
  [FR] La présente invention concerne de nouveaux composés de formule (I), ou des sels pharmaceutiquement acceptables de ces composés, présentant une activité agoniste inverse ou antagoniste des récepteurs du glucagon, ainsi que des procédés de préparation de ces composés. Dans un autre mode de réalisation, l'invention concerne des compositions pharmaceutiques comprenant des composés de formule (I) ainsi que leurs méthodes d'utilisation pour traiter le diabète et d'autres troubles métaboliques associés au glucagon, et analogues.